Navigation Links
Pharmasset Reports Fiscal Year End 2009 Financial Results
Date:11/25/2009

ngle ascending dose study was conducted that assessed the safety, tolerability and pharmacokinetics of PSI-7851 in healthy subjects at doses ranging from 25mg to 800mg. PSI-7851 was found to be generally safe and well tolerated and, therefore, was advanced into a multiple ascending dose trial.

In June 2009, we initiated a phase 1 multiple ascending dose (MAD) study in HCV-infected patients. Subjects were enrolled at two U.S. centers and randomized to PSI-7851 (8 per cohort) or placebo (2 per cohort). Final results from the MAD study were presented in a late breaker poster at AASLD on November 2, 2009. In the MAD study, PSI-7851 was generally safe and well tolerated across all cohorts with no discontinuations, no serious adverse events, and no dose-related trends in adverse events or laboratory abnormalities. Further, PSI-7851 demonstrated dose-dependent potent antiviral activity with a maximum mean HCV RNA decrease of 1.95 log10 IU/mL in patients receiving 50mg QD, 100mg QD, 200mg QD and 400mg QD administered for 3 days.

PSI-938 and PSI-879

During 2009, we nominated two development candidates from our purine nucleotide analog polymerase inhibitor program for the treatment of chronic HCV. In June 2009, we nominated PSI-938 for further pre-clinical development required for an application with the FDA or equivalent foreign regulatory agency to begin clinical studies. Our plan is to submit an IND, or its foreign equivalent, during the first calendar quarter of 2010.

In September 2009, we nominated a second purine nucleotide analog, PSI-879, for pre-clinical development. PSI-879 differs from PSI-938 in the prodrug technology that it employs. We anticipate filing an IND, or its foreign equivalent, for PSI-879 in the fourth quarter of 2010.

Termination of Clevudine Registration Trials

On April 20, 2009, following consultations with our independent Data Safety Monitoring Board and the FDA, w
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
4. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
5. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
6. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Pharmasset Reports Fiscal Year End 2008 Financial Results
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners participated ... to Benefit the Radiation Oncology Institute (ROI), hosted by ... Golden Gate Park in San Francisco.  ... , CEO of Radiation Business Solutions, "but at ... raised over $70,000 for the ROI this year. This ...
(Date:9/19/2014)...  CytRx Corporation (Nasdaq: CYTR ), a ... announced that David J. Haen , Vice President, ... the Biotech Industry Conference on Friday, September 26 th ... place at the Millennium Broadway Hotel in ... and archived webcast of the presentation will be available ...
(Date:9/19/2014)... VIENNA, Austria , September 19, 2014 ... glucose control persist for many years in people with ... to produce major long term benefits for the kidneys." ... control in patients with type 2 diabetes leads to ... to usual care. The global study has ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Hope for Treatment of,Children, WHITE PLAINS, N.Y., Feb. ... rare craniofacial birth defect in,mice and holds promise to ... funded in part by the March of Dimes., ... Nature Medicine,demonstrates the potential for translating basic research into ...
... BEIJING, Feb. 6 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,Inc. ... "Company"), a,pharmaceutical company in the People,s Republic ... achieved significant milestones in the development of,isosorbide ... drug,for the prevention and treatment of angina., ...
Cached Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 3
(Date:9/21/2014)... the physical activity benefits of active play, a new ... children, playing has no goal it is an ... alone or with friends, and it represents "an opportunity ... boredom, sadness, fear, or loneliness." "By focusing on the ... aspects of play that are beneficial to young people,s ...
(Date:9/21/2014)... BC (PRWEB) September 21, 2014 Burnaby ... educational information to clients in order to help them ... sessions held at the clinic that will help clients ... they can also take active participation in the healing ... and posture, clients will be able to facilitate the ...
(Date:9/21/2014)... 2014 Over the past five years, ... inundate the market, thereby cutting into revenue growth for ... to data from Industry Canada, the loss of patent ... and $2.5 billion in 2010 and 2012, respectively. “In ... which has hampered revenue growth, many pharmaceutical manufacturers have ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
(Date:9/21/2014)... SUNDAY, Sept. 21, 2014 (HealthDay News) -- Young women ... and know which foods they should eat. But they ... nutritional choices, according to a new study. ... the University of Illinois,s Peer Education Exercising and Eating ... what would they choose to eat if they were ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News: College Women Can Use Food Strategies, Study Finds 2
... Oct. 8 Boston Scientific,(NYSE: BSX ) announced ... third quarter results, which it plans to report on ... a $250 million milestone,payment from Abbott Laboratories (NYSE: ... Guidant,s vascular intervention and endovascular,solutions businesses. As a result, ...
... Weight Watchers,International, Inc. (NYSE: WTW ) ... serve as its President, North America, effective November,3, ... product,operations and general management experience, will oversee the ... products,publishing and licensing businesses and will be reporting ...
... sometimes goes awry has been implicated in breast cancer. ... of the Notch pathway may contribute to breast cancer. ... Drs Jane Visvader and Geoff Lindeman from the Victorian ... Notch genes in regulating breast development and function. ...
... Bulletin Board:,VYTC) today announced that effective October 7, ... an independent scientific consultant to Vyta Corp.,Dr. Sorgente ... at,BIOAGRA, LLC, a joint venture, equally owned by ... 2008, Vyta Corp announced its filing of,foreclosure litigation ...
... 8 Mass casualty incidents --,such as terrorist ... or hurricanes -- raise the life-and-death reality that,existing ... for all who,need it. One of the most ... requiring respiratory support., Disaster specialists and health ...
... Tampa, FL (Oct. 8, 2008) Women, the elderly, ... are all less likely to receive same-day coronary angioplasty ... South Florida researchers found. Their study was published this ... Cardiology . , Angioplasty, also known as percutaneous ...
Cached Medicine News:Health News:Boston Scientific Announces Third Quarter Adjustments 2Health News:Boston Scientific Announces Third Quarter Adjustments 3Health News:Boston Scientific Announces Third Quarter Adjustments 4Health News:Boston Scientific Announces Third Quarter Adjustments 5Health News:Weight Watchers Names Steven C. McCormick as President, North America 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 3Health News:Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 3Health News:Florida study finds barriers to angioplasty for life-threatening heart attacks 2Health News:Florida study finds barriers to angioplasty for life-threatening heart attacks 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: